Online tool to guide decisions for BRCA1/2 mutation carriers

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 497-506

  Kurian, Allison W ^a   Munoz, Diego F ^a   Rust, Peter ^b   Schackmann, Elizabeth A ^a   Smith, Michael ^b   Clarke, Lauren ^b   Mills, Meredith A ^a   Plevritis, Sylvia K ^a  

^a STANFORD UNIVERSITY   (United States)

^b Cornerstone Systems Northwest ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL DECISION MAKING; FEMALE; GENE MUTATION; HUMAN; INFORMATION SERVICE; MAJOR CLINICAL STUDY; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE;

BREAST NEOPLASMS; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; INCIDENCE; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MASTECTOMY; MONTE CARLO METHOD; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 84863116556     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.6060     Document Type: Article

References (104)

1. Antoniou A, Pharoah PD, Narod S, et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet 72:1117-1130, 2003 (Pubitemid 36530000)
2. Chen S, Parmigiani G: Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25: 1329-1333, 2007 (Pubitemid 46706879)
3. Domchek SM, Friebel TM, Neuhausen SL, et al: Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: A prospective cohort study. Lancet Oncol 7:223-229, 2006 (Pubitemid 43286452)
4. Domchek SM, Friebel TM, Singer CF, et al: Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967-975, 2010
5. Kauff ND, Domchek SM, Friebel TM, et al: Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: A multicenter, prospective study. J Clin Oncol 26:1331-1337, 2008
6. Rebbeck TR, Kauff ND, Domchek SM: Metaanalysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101:80-87, 2009
7. Hagen AI, Kvistad KA, Maehle L, et al: Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. Breast 16:367-374, 2007 (Pubitemid 47157808)
8. Kriege M, Brekelmans CT, Peterse H, et al: Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. Breast Cancer Res Treat 102:357-363, 2007 (Pubitemid 46474846)
9. Kuhl CK, Schrading S, Leutner CC, et al: Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23:8469-8476, 2005
10. Leach MO, Boggis CR, Dixon AK, et al: Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: A prospective multicentre cohort study (MARIBS). Lancet 365:1769-1778, 2005 (Pubitemid 40744657)
11. Trecate G, Vergnaghi D, Bergonzi S, et al: Breast MRI screening in patients with increased familial and/or genetic risk for breast cancer: A preliminary experience. Tumori 89:125-131, 2003 (Pubitemid 36745213)
12. Warner E, Hill K, Causer P, et al: Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol 29:1664-1669, 2011
13. Atchley DP, Albarracin CT, Lopez A, et al: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 26:4282-4288, 2008
14. Bresser PJ, Seynaeve C, Van Gool AR, et al: Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women. Plast Reconstr Surg 117:1675-1682, 2006 (Pubitemid 44324344)
15. Foulkes WD, Metcalfe K, Sun P, et al: Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: The influence of age, grade, and histological type. Clin Cancer Res 10:2029-2034, 2004 (Pubitemid 38375563)
16. Gonzalez-Angulo AM, Timms KM, Liu S, et al: Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 17:1082-1089, 2011
17. Hartmann LC, Sellers TA, Schaid DJ, et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93:1633-1637, 2001 (Pubitemid 33094870)
18. Metcalfe K, Lynch HT, Ghadirian P, et al: Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328-2335, 2004 (Pubitemid 41115389)
19. Rebbeck TR, Friebel T, Lynch HT, et al: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 22:1055-1062, 2004 (Pubitemid 41095038)
20. Rennert G, Bisland-Naggan S, Barnett- Griness O, et al: Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357:115-123, 2007 (Pubitemid 47057729)
21. Robson M, Hensley M, Barakat R, et al: Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 89:281-287, 2003 (Pubitemid 36457877)
22. Tercyak KP, Peshkin BN, Brogan BM, et al: Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 25:285-291, 2007 (Pubitemid 350003016)
23. Tung N, Wang Y, Collins LC, et al: Estrogen receptor positive breast cancers in BRCA1 mutation carriers: Clinical risk factors and pathologic features. Breast Cancer Res 12:R12, 2010
24. Daly MB, Axilbund JE, Buys S, et al: Genetic/ familial high-risk assessment: Breast and ovarian. J Natl Compr Canc Netw 8:562-594, 2010
25. Anderson K, Jacobson JS, Heitjan DF, et al: Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144:397-406, 2006 (Pubitemid 46768161)
26. Armstrong K, Schwartz JS, Randall T, et al: Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: A decision analysis. J Clin Oncol 22:1045-1054, 2004 (Pubitemid 41095037)
27. Grann VR, Jacobson JS, Thomason D, et al: Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: An updated decision analysis. J Clin Oncol 20:2520-2529, 2002 (Pubitemid 34525739)
28. Grann VR, Patel PR, Jacobson JS, et al: Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 125:837-847, 2011
29. Kurian AW, Sigal BM, Plevritis SK: Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 28:222-231, 2010
30. Lee JM, Kopans DB, McMahon PM, et al: Breast cancer screening in BRCA1 mutation carriers: Effectiveness of MR imaging - Markov Monte Carlo decision analysis. Radiology 246:763-771, 2008
31. Plevritis SK, Kurian AW, Sigal BM, et al: Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 295:2374-2384, 2006 (Pubitemid 43788105)
32. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis: Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336:1465-1471, 1997 (Pubitemid 27208615)
33. Schrag D, Kuntz KM, Garber JE, et al: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283:617-624, 2000 (Pubitemid 30069177)
34. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in long-term breast carcinoma survivors: A longitudinal investigation. Cancer 106:751-758, 2006 (Pubitemid 43238440)
35. Earle CC, Chapman RH, Baker CS, et al: Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302-3317, 2000
36. Ganz PA, Kwan L, Stanton AL, et al: Physical and psychosocial recovery in the year after primary treatment of breast cancer. J Clin Oncol 29:1101-1109, 2011
37. Evans DG, Shenton A, Woodward E, et al: Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 8:155, 2008
38. Ford D, Easton DF, Stratton M, et al: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689, 1998 (Pubitemid 28164626)
39. King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643-646, 2003 (Pubitemid 37310920)
40. Eisen A, Lubinski J, Klijn J, et al: Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: An international case-control study. J Clin Oncol 23:7491-7496, 2005 (Pubitemid 46291812)
41. Kramer JL, Velazquez IA, Chen BE, et al: Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol 23:8629- 8635, 2005
42. Finch A, Beiner M, Lubinski J, et al: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296: 185-192, 2006
43. Tilanus-Linthorst MM, Obdeijn IM, Hop WC, et al: BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13:7357-7362, 2007
44. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
45. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292: 1317-1325, 2004 (Pubitemid 39223222)
46. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
47. Colditz GA, Willett WC, Stampfer MJ, et al: Menopause and the risk of coronary heart disease in women. N Engl J Med 316:1105-1110, 1987 (Pubitemid 17052498)
48. Melton LJ, Khosla S, Malkasian GD, et al: Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 18:900-905, 2003 (Pubitemid 37294974)
49. Rocca WA, Bower JH, Maraganore DM, et al: Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 69:1074-1083, 2007 (Pubitemid 47517552)
50. Rocca WA, Grossardt BR, de Andrade M, et al: Survival patterns after oophorectomy in premenopausal women: A population-based cohort study. Lancet Oncol 7:821-828, 2006 (Pubitemid 44464065)
51. Saslow D, Boetes C, Burke W, et al: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75-89, 2007 (Pubitemid 46535708)
52. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784- 1792, 2005
53. Plevritis SK, Sigal BM, Salzman P, et al: Chapter 12: a stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr 36:86-95, 2006
54. Carlson RW, Allred DC, Anderson BO, et al: Breast cancer. Clinical practice guidelines in oncology, Version 2.2011. http://www.nccn.org
55. Chappuis PO, Nethercot V, Foulkes WD: Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol 18:287-295, 2000 (Pubitemid 30253021)
56. Stolier AJ, Corsetti RL: Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation. Am Surg 71:1031-1033, 2005
57. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122:2017-2022, 2008 (Pubitemid 351441190)
58. Wainberg S, Husted J: Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 13:1989-1995, 2004 (Pubitemid 40054290)
59. Bayraktar S, Gutierrez-Barrera AM, Liu D, et al: Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat 130:145-153, 2011
60. Lee LJ, Alexander B, Schnitt SJ, et al: Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 117:3093-3100, 2011
61. Eisen A, Lubinski J, Gronwald J, et al: Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 100: 1361-1367, 2008
62. Rebbeck TR, Friebel T, Wagner T, et al: Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol 23:7804-7810, 2005 (Pubitemid 46657377)
63. Rossouw JE, Anderson GL, Prentice RL, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333, 2002 (Pubitemid 34761611)
64. Brohet RM, Goldgar DE, Easton DF, et al: Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25: 3831-3836, 2007 (Pubitemid 47477257)
65. Gronwald J, Tung N, Foulkes WD, et al: Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update. Int J Cancer 118: 2281-2284, 2006
66. Jernström H, Loman N, Johannsson OT, et al: Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 41:2312-2320, 2005 (Pubitemid 41415608)
67. King MC, Wieand S, Hale K, et al: Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251-2256, 2001 (Pubitemid 33063147)
68. Milne RL, Knight JA, John EM, et al: Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev 14:350-356, 2005 (Pubitemid 40270096)
69. Modan B, Hartge P, Hirsh-Yechezkel G, et al: Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235-240, 2001 (Pubitemid 32695062)
70. University of California, Berkeley: Berkeley Mortality Database. http://www.demog.berkeley.edu/~bmd/States/ssa/life.tables/ufgen.lt.1x1
71. Centers for Disease Control and Prevention: National Vital Statistics System, Worktable 292R: Death rates for 358 selected causes by 5-year age groups, race, and sex-United States, 1999-2004. http://www.cdc.gov/nchs
72. Parker WH, Broder MS, Liu Z, et al: Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol 106:219-226, 2005 (Pubitemid 41023257)
73. FORCE: Facing Our Risk of Cancer Empowered. http://www.facingourrisk.org
74. Singletary SE, Connolly JL: Breast cancer staging: Working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 56:37-47, 2006 (Pubitemid 43228386)
75. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005 (Pubitemid 46179461)
76. Ravdin PM, Siminoff LA, Davis GJ, et al: Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991, 2001 (Pubitemid 32176272)
77. Stanford University Cancer Institute: BRCA Decision Tool. http://brcatool.stanford.edu
78. Amir E, Freedman OC, Seruga B, et al: Assessing women at high risk of breast cancer: A review of risk assessment models. J Natl Cancer Inst 102:680-691, 2010
79. Ravdin PM: The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res (Phila) 3:686-688, 2010
80. Begg CB, Haile RW, Borg A, et al: Variation of breast cancer risk among BRCA1/2 carriers. JAMA 299:194-201, 2008
81. Simchoni S, Friedman E, Kaufman B, et al: Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A 103:3770-3774, 2006 (Pubitemid 43376630)
82. Tryggvadottir L, Sigvaldason H, Olafsdottir GH, et al: Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000. J Natl Cancer Inst 98:116-122, 2006 (Pubitemid 43159966)
83. Haroun I, Graham T, Poll A, et al: Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer. Breast 20:254-258, 2011
84. Staton AD, Kurian AW, Cobb K, et al: Cancer risk reduction and reproductive concerns in female BRCA1/2 mutation carriers. Fam Cancer 7:179-186, 2008
85. Grann VR, Jacobson JS, Sundararajan V, et al: The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations. Cancer J Sci Am 5:283-292, 1999 (Pubitemid 29471533)
86. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al: Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: A more prominent role for oophorectomy. J Clin Oncol 20: 2092-2100, 2002 (Pubitemid 34408800)
87. Brace C, Schmocker S, Huang H, et al: Physicians' awareness and attitudes toward decision aids for patients with cancer. J Clin Oncol 28:2286-2292, 2010
88. Leighl NB, Shepherd HL, Butow PN, et al: Supporting treatment decision making in advanced cancer: A randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol 29:2077-2084, 2011
89. O'Brien MA, Whelan TJ, Villasis-Keever M, et al: Are cancer-related decision aids effective? A systematic review and meta-analysis. J Clin Oncol 27:974-985, 2009
90. Sepucha KR, Belkora JK, Tripathy D, et al: Building bridges between physicians and patients: Results of a pilot study examining new tools for collaborative decision making in breast cancer. J Clin Oncol 18:1230-1238, 2000 (Pubitemid 30159840)
91. van Roosmalen MS, Stalmeier PF, Verhoef LC, et al: Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. Br J Cancer 90:333-342, 2004 (Pubitemid 38250625)
92. Waljee JF, Rogers MA, Alderman AK: Decision aids and breast cancer: Do they influence choice for surgery and knowledge of treatment options? J Clin Oncol 25:1067-1073, 2007 (Pubitemid 46596758)
93. Chao C, Studts JL, Abell T, et al: Adjuvant chemotherapy for breast cancer: How presentation of recurrence risk influences decision-making. J Clin Oncol 21:4299-4305, 2003 (Pubitemid 46621805)
94. Plevritis SK, Salzman P, Sigal BM, et al: A natural history model of stage progression applied to breast cancer. Stat Med 26:581-595, 2007 (Pubitemid 46139540)
95. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al: Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer 43:867-876, 2007 (Pubitemid 46366688)
96. Lakhani SR, Van De Vijver MJ, Jacquemier J, et al: The pathology of familial breast cancer: Predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310-2318, 2002 (Pubitemid 34441658)
97. Robson ME, Chappuis PO, Satagopan J, et al: A combined analysis of outcome following breast cancer: Differences in survival based on BRCA1/ BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 6:R8-R17, 2004
98. Antoniou AC, Sinilnikova OM, Simard J, et al: RAD51 135G->C modifies breast cancer risk among BRCA2 mutation carriers: Results from a combined analysis of 19 studies. Am J Hum Genet 81:1186-1200, 2007 (Pubitemid 350211449)
99. Rebbeck TR, Mitra N, Domchek SM, et al: Modification of BRCA1-associated breast and ovarian cancer risk by BRCA1 interacting genes. Cancer Res 71:5792-5805, 2011
100. Kuhl CK, Schrading S, Bieling HB, et al: MRI for diagnosis of pure ductal carcinoma in situ: A prospective observational study. Lancet 370:485-492, 2007 (Pubitemid 47214635)
101. Audeh MW, Carmichael J, Penson RT, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376:245-251, 2010
102. Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361:123-134, 2009
103. O'Shaughnessy J, Osborne C, Pippen JE, et al: Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205-214, 2011
104. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: A proof-of-concept trial. Lancet 376:235-244, 2010